Table 1 Baseline characteristics of the participants by serum AOPP categories
Variables | Baseline serum AOPP, µmol/L | P-value | |
|---|---|---|---|
 < 87 |  ≥ 87 | ||
N | 1126 | 441 | Â |
Male, no. (%) | 649 (57.6) | 247 (56.0) | 0.558 |
Age, year | 55.0 ± 15.6 | 58.4 ± 14.2 |  < 0.001 |
Dialysis vintage, month | 28.9 (11.8–60.5) | 35.1 (18.6–67.9) |  < 0.001 |
BMI, kg/m2 | 21.3 ± 3.3 | 22.2 ± 3.7 |  < 0.001 |
MAP, mmHg | 103.1 ± 14.0 | 101.6 ± 14.3 | 0.055 |
Smoking, no. (%) | 134 (11.9) | 66 (15.0) | 0.102 |
CVD, no. (%) | 562 (49.9) | 241 (54.6) | 0.092 |
Diabetes, no. (%) | 557 (49.5) | 262 (59.4) |  < 0.001 |
Hypertension, no. (%) | 1028 (91.3) | 410 (93.0) | 0.278 |
Laboratory results | Â | Â | Â |
 C-reactive protein, mg/L | 3.4 (1.8–10.3) | 4.7 (2.9–10.3) | 0.011 |
 Albumin, g/L | 39.7 ± 6.3 | 39.6 ± 6.8 | 0.886 |
 Hemoglobin, g/L | 102.4 ± 20.5 | 105.4 ± 18.7 | 0.008 |
 White blood cells, 109/L | 5.9 ± 1.9 | 6.2 ± 2.0 | 0.009 |
 Calcium, mmol/L | 2.2 ± 0.3 | 2.3 ± 0.3 | 0.055 |
 Phosphate, mmol/L | 1.9 ± 0.7 | 2.1 ± 0.7 |  < 0.001 |
 iPTH, pg/mL | 258 (131.2–500.3) | 280.7 (138.5–608.9) | 0.147 |
 Total cholesterol, mmol/L | 4.0 ± 1.0 | 4.4 ± 1.2 |  < 0.001 |
 TG, mmol/L | 1.1 (0.8–1.6) | 1.8 (1.1–2.7) |  < 0.001 |
 AOPP, μmol/L | 68 ± 11 | 105 ± 19 |  < 0.001 |
Medication use, no. (%) | Â | Â | Â |
 ACEI/ARB | 564 (50.1) | 214 (48.5) | 0.578 |
 Glucose-lowering drugs | 135 (12.0) | 85 (19.3) |  < 0.001 |
 Lipid-lowering drugs | 98 (8.7) | 42 (9.5) | 0.609 |
 Antiplatelet drugs | 146 (13.0) | 51 (11.6) | 0.452 |
 Iron supplement | 598 (53.1) | 219 (49.7) | 0.219 |
 Phosphorus binder | 439 (39.0) | 205 (46.5) | 0.007 |